

DAFTAR PUSTAKA

- Allredge, B.K., Corelli, R.L., dan Ernst, M.E., 2012. *Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins.
- Badve, S.V., Beller, E.M., Cass, A., Francis, D.P., Hawley, C., Macdougall, I.C., dkk., 2013. Interventions for erythropoietin-resistant anaemia in dialysis patients. *The Cochrane Database of Systematic Reviews*, **8**: CD006861.
- Burns, M.A.C., Wells, B.G., dan Schwinghammer, T.L., 2008. *Pharmacotherapy Principles & Practice*. Mc Graw Hill Medical, United State.
- Dahlan, M.S., 2013. *Besar Sampel Dan Cara Pengambilan Sampel*, 3rd ed, Evidence Based Medicine. Salemba Medika, Jakarta.
- Deicher, R. dan Hörl, W.H., 2004. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. *Drugs*, **64**: 499–509.
- DeLong, M., Logan, J.L., dan Yong, K.-C., 2005. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. *Nephrology Dialysis Transplantation*, **20**: 585–590.
- Dipiro, J.T., Talbert, R.L., dan Yee, G.C., 2008. *Pharmacotherapy A Pathophysiologic Approach*, 7th ed. Mc Graw Hill Medical, United State.
- Efrati, S., Zaidenstein, R., Dishy, V., 2002. ACE inhibitors and survival of hemodialysis patients. *Am J Kidney Dis*, **40**: 1023–1029.
- Francisco, A.L.M. de, 2010. Individualizing anaemia therapy. *NDT Plus*, **3**: 519–526.

- Freudenthaler, Schreeb, Körner, Gleiter, dan Gleiter, 1999. Angiotensin II increases erythropoietin production in healthy human volunteers. *European Journal of Clinical Investigation*, **29**: 816–823.
- Hess, E., Sperschneider, H., dan Stein, G., 1996. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, **11**: 749–751.
- Hörl, W.H., 2013. Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease. *Drugs*, **73**: 117–130.
- James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., dkk., 2014. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*, **311**: 507–520.
- Johnson, D.W., Pollock, C.A., dan Macdougall, I.C., 2007. Erythropoiesis-stimulating agent hyporesponsiveness (Review Article). *Nephrology*, **12**: 321–330.
- KDIGO Anemia Workgroup, 2012. *KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease*, Supplements. ed. Kidney International.
- KDOQI dan National Kidney Foundation, 2006. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **47**: S11–145.
- Kidney Disease Outcomes Quality Initiative (K/DOQI), 2004. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **43**: S1–290.

- Kilpatrick, R.D., Critchlow, C.W., Fishbane, S., Besarab, A., Stehman-Breen, C., Krishnan, M., dkk., 2008. Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients. *Clinical Journal of the American Society of Nephrology*, **3**: 1077–1083.
- Laurance L Brunton, Lazo, J.S., dan Parker, K.L., 2006. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 11th ed. Mc Graw Hill Medical, United State.
- Levin, N.W., Kotanko, P., Eckardt, K.-U., Kasiske, B.L., Chazot, C., Cheung, A.K., dkk., 2009. Blood pressure in chronic kidney disease stage 5D—report from a Kidney Disease: Improving Global Outcomes controversies conference. *Kidney International*, **77**: 273–284.
- Locatelli, F., 2004. The revised European Best Practice Guidelines (EBPG) for the Management of Anemia in Patients with Chronic Renal Failure. *Nephrology Dialysis Transplantation*, **19**: iii.
- Locatelli, F., Covic, A., Eckardt, K.-U., Wiecek, A., dan Vanholder, R., 2009. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). *Nephrology Dialysis Transplantation*, **24**: 348–354.
- Locatelli, F., Aljama, P., Canaud, B., Covic, A., Francisco, A.D., Macdougall, I.C., dkk., 2010. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. *Nephrology Dialysis Transplantation*, gfq336.
- Longo, Fauci, dan Kasper, 2012. *Harrisons's Principles of Internal Medicine*, 18 th. ed. United State.
- López-Gómez, J.M., Portolés, J.M., dan Aljama, P., 2008. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. *Kidney International. Supplement*, S75–81.
- Loughnan, A., Rahman, G., dan Abeygunasekara, S.C., 2011. Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients. *Informa Healthcare*, .

- Maccougall, I.C., 1999. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. *Nephrology Dialysis Transplantation*, **14**: 1836–1841.
- Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., dkk., 2013. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of Hypertension*, **31**: 1281–1357.
- McCullough, P., Sandberg, K., Yee, J., 2002. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. *J Renin Angiotensin Aldosterone Syst*, **3**: 188–191.
- McLean, E., Cogswell, M., Egli, I., Wojdyla, D., dan de Benoist, B., 2009. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. *Public Health Nutrition*, **12**: 444–454.
- National High Blood Pressure Education Program, 2004. *The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure*. National Heart, Lung, and Blood Institute (US), Bethesda (MD).
- National Kidney Foundation, 2002. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **39**: S1–266.
- PERNEFRI, 2011. *Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik*, II. ed. PERNEFRI, Jakarta.
- Pratt, M.C., Lewis-Barned, N.J., Walker, R.J., Bailey, R.R., Shand, B.I., dan Livesey, J., 1992. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. *British Journal of Clinical Pharmacology*, **34**: 363–365.
- Ribeiro, S., costa, elisio, belo, luis, 2013. rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits.

- Singh, A.K., 2010. ESAs in Dialysis Patients: Are You a Hedgehog or a Fox? *Journal of the American Society of Nephrology*, **21**: 543–546.
- Suctonia, C.P., Valeria, S., Dimitris, M., Georgia, S., 2014. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. *Cochrane Database Syst. Rev.*
doi:10.1002/14651858.CD010590.pub2
- Walter, J., 1993. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? *Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association*, **8**: 1428.
- Winnicki, W., Prehslauer, A., Kletzmayr, J., Herkner, H., Sunder-Plassmann, G., Brunner, M., dkk., 2012. Lisinopril pharmacokinetics and erythropoietin requirement in haemodialysis patients. *European Journal of Clinical Investigation*, **42**: 1087–1093.
- Zannad, F., Kessler, M., Lehert, P., Grünfeld, J.P., Thuilliez, C., Leizorovicz, A., dkk., 2006. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. *Kidney International*, **70**: 1318–1324.